Nicholas S. Moore, MD
Assistant Professor of Therapeutic RadiologyAbout
Research
Publications
2025
Prediction of Lymph Node Metastasis in Non–Small Cell Lung Carcinoma Using Primary Tumor Somatic Mutation Data
Lee V, Moore N, Doyle J, Hicks D, Oh P, Bodofsky S, Hossain S, Patel A, Aneja S, Homer R, Park H. Prediction of Lymph Node Metastasis in Non–Small Cell Lung Carcinoma Using Primary Tumor Somatic Mutation Data. JCO Clinical Cancer Informatics 2025, 9: e2400303. PMID: 40446175, DOI: 10.1200/cci-24-00303.Peer-Reviewed Original ResearchThis study investigates machine learning models using tumor genetic data to predict lymph node metastasis in lung cancer, showing improved accuracy over traditional methods and more potential for personalized treatment.
2024
443 Myeloid Immunometabolic Reprogramming Mitigates Chronic Neurodegeneration After Experimental Traumatic Brain Injury
Moore N, Jarrahi A, Lu Y, Khodadadi H, Jones E, Kaoutzani L, Vale F, Vender J, Baban B, Dhandapani K. 443 Myeloid Immunometabolic Reprogramming Mitigates Chronic Neurodegeneration After Experimental Traumatic Brain Injury. Neurosurgery 2024, 70: 135-135. DOI: 10.1227/neu.0000000000002809_443.Peer-Reviewed Original ResearchExperience traumatic brain injuriesT cellsMyeloid cellsChronic inflammationNaive splenic T cellsT cells ex vivoMetabolic reprogrammingAuto-reactive T cellsTraumatic brain injuryDegree of chronic inflammationT cell primingLong-term consequencesProgressive neurodegenerationImmune cell infiltrationSevere traumatic brain injurySplenic T cellsWhite matter injuryPre-clinical modelsProgressive white matter lossWhite matter lossControlled cortical impactMagnetic resonance imagingExperimental traumatic brain injuryBrain injuryWeeks post-injuryRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically Effective DoseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failureIntegrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma
Han S, Camp S, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker C, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri T, AlDubayan S, Van Allen E. Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma. European Urology Open Science 2024, 62: 107-122. PMID: 38496821, PMCID: PMC10940785, DOI: 10.1016/j.euros.2024.02.006.Peer-Reviewed Original ResearchCopy number variantsGermline pathogenic variantsCryptic splice variantsNon-clear cell renal cell carcinomaCell renal cell carcinomaRare inherited mutationsRenal cell carcinomaPathogenic variantsSomatic eventsPopulation stratificationRisk of kidney cancerAge of cancer onsetGermline copy number variantsSplice variantsBurden of pathogenic variantsCell carcinomaEstimation of genetic riskRenal cell carcinoma riskRCC patientsCancer-free controlsCase-control analysisCase-control studyRenal cell carcinoma patientsClear cell renal cell carcinomaGermline rare variants
2023
Recombinant human DNase-I improves acute respiratory distress syndrome via neutrophil extracellular trap degradation
Jarrahi A, Khodadadi H, Moore N, Lu Y, Awad M, Salles E, Vaibhav K, Baban B, Dhandapani K. Recombinant human DNase-I improves acute respiratory distress syndrome via neutrophil extracellular trap degradation. Journal Of Thrombosis And Haemostasis 2023, 21: 2473-2484. PMID: 37196848, PMCID: PMC10185489, DOI: 10.1016/j.jtha.2023.04.044.Peer-Reviewed Original ResearchConceptsAcute respiratory distress syndromeNeutrophil extracellular trapsExperimental ARDSRecombinant human DNase IAdministration of rhDNaseRespiratory distress syndromeDistress syndromeAberrant coagulationIntravenous administrationExcessive inflammationPlatelet activationHuman DNase IDegradation of neutrophil extracellular trapsExperimental acute respiratory distress syndromeFood and Drug Administration-approved drugsNeutrophil extracellular trap degradationEffect of rhDNaseBronchoalveolar lavage fluidAssociated with excessive inflammationHypoxic lung tissueIntravenous placeboRandomized to treatment armsMultiorgan failureRespiratory failureInterstitial inflammationInflammaging, cellular senescence, and cognitive aging after traumatic brain injury
Lu Y, Jarrahi A, Moore N, Bartoli M, Brann D, Baban B, Dhandapani K. Inflammaging, cellular senescence, and cognitive aging after traumatic brain injury. Neurobiology Of Disease 2023, 180: 106090. PMID: 36934795, PMCID: PMC10763650, DOI: 10.1016/j.nbd.2023.106090.Peer-Reviewed Original ResearchConceptsTraumatic brain injuryCognitive agingCognitive declineRepetitive mild traumatic brain injuryMild traumatic brain injuryBrain injuryYears post-TBITraumatic brain injury outcomesSenescent Associated Secretory PhenotypeCognitive dysfunctionPost-TBIPre-clinicalNeurodegenerative changesCellular senescenceAssociated with mortalitySenescent cellsNeurological deteriorationImmune activationClinical dataClinical evidenceSecretory phenotypeNeurodegenerationProgressive neurodegenerationFunctional associationExtrinsic causesBladder Cancer Radiation Oncology of the Future: Prognostic Modelling, Radiomics, and Treatment Planning With Artificial Intelligence
Moore N, McWilliam A, Aneja S. Bladder Cancer Radiation Oncology of the Future: Prognostic Modelling, Radiomics, and Treatment Planning With Artificial Intelligence. Seminars In Radiation Oncology 2023, 33: 70-75. PMID: 36517196, DOI: 10.1016/j.semradonc.2022.10.009.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsArtificial intelligenceMachine learningReliability of algorithmAccurate predictive modelsEfficient creationIntelligenceBladder cancer patientsRadiation oncology patientsAlgorithmPrognostic modellingRoutine clinical useClinical outcomesOncology patientsClinical recordsCancer patientsBladder cancerPredictive modelTreatment planClinical useMultiple treatment plansClinical implementationNext stepRadiation oncologyTreatment planningInterpretability
2022
Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients
Liu K, Poux N, Shin K, Moore N, Chen Y, Margossian S, Whangbo J, Duncan C, Lehmann L, Marcus K. Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. Transplantation And Cellular Therapy 2022, 28: 502.e1-502.e12. PMID: 35623615, PMCID: PMC11075968, DOI: 10.1016/j.jtct.2022.05.028.Peer-Reviewed Original ResearchConceptsGraft-versus-host diseaseBusulfan-based myeloablative conditioningChronic graft-versus-host diseaseAllogeneic hematopoietic stem cell transplantationHematopoietic stem cell transplantationMyeloablative conditioning regimensStem cell transplantationPulmonary toxicityLong-term incidenceMyeloablative conditioningAllo-HSCTMyelodysplastic syndromeTBI-basedConditioning regimensOverall survivalCell transplantationPediatric patientsPost-transplantationCumulative incidenceAcute graft-versus-host diseaseGrade 5 pulmonary toxicityIncidence of pulmonary toxicityOccurrence of grade 3Pediatric allo-HSCT recipientsAssociated with inferior OSRapid expansion and extinction of antibiotic resistance mutations during treatment of acute bacterial respiratory infections
Chung H, Merakou C, Schaefers M, Flett K, Martini S, Lu R, Blumenthal J, Webster S, Cross A, Al Ahmar R, Halpin E, Anderson M, Moore N, Snesrud E, Yu H, Goldberg J, O’Toole G, McGann P, Stam J, Hinkle M, McAdam A, Kishony R, Priebe G. Rapid expansion and extinction of antibiotic resistance mutations during treatment of acute bacterial respiratory infections. Nature Communications 2022, 13: 1231. PMID: 35264582, PMCID: PMC8907320, DOI: 10.1038/s41467-022-28188-w.Peer-Reviewed Original ResearchConceptsAntibiotic resistance mutationsResistance mutationsLong-read sequencingEvolution of antibiotic resistanceSputum samplesRespiratory infectionsCulture-based methodsLow-frequency resistance mutationsColonization bottlenecksEarly stages of infectionDays of therapyAcute bacterial infectionBacterial respiratory infectionsMechanically Ventilated PatientsGenomic surveillanceResistance phenotypeStages of infectionAntibiotic resistanceIn vivo frequencyAntibiotic therapyAntibiotic changeMutationsAntibiotic switchTherapy choiceIndividual patients
2021
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology
Reardon B, Moore N, Moore N, Kofman E, AlDubayan S, Cheung A, Conway J, Elmarakeby H, Imamovic A, Kamran S, Keenan T, Keliher D, Konieczkowski D, Liu D, Mouw K, Park J, Vokes N, Dietlein F, Van Allen E. Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. Nature Cancer 2021, 2: 1102-1112. PMID: 35121878, PMCID: PMC9082009, DOI: 10.1038/s43018-021-00243-3.Peer-Reviewed Original ResearchConceptsMolecular profilingAssociated with clinical outcomesIdentified therapeutic strategiesTumor molecular profilingIndividual's molecular profileMolecular featuresGenomic dataOpen-source computational methodClinical outcomesRetrospective cohortTrial cohortGenomic alterationsTherapeutic strategiesTherapeutic approachesPoint-of-care decision makingPrecision oncologyGlobal molecular featuresPatientsClinical hypothesisCohortClinical frameworkKnowledge basesAlterations
Clinical Care
Overview
Nicholas S. Moore, MD, is a radiation oncologist specializing in therapeutic radiology. He focuses on treating central nervous system tumors in both adults and children, as well as managing cancers of the genitourinary system, head and neck, gastrointestinal tract, and blood. He utilizes advanced radiation techniques to target these malignancies.
As an assistant professor of therapeutic radiology at Yale School of Medicine, Dr. Moore is involved in research that applies artificial intelligence to enhance the precision and effectiveness of cancer treatments.
Dr. Moore earned his medical degree from Harvard Medical School, completing his internship in internal medicine at Beth Israel Deaconess Medical Center. He pursued residency training in therapeutic radiology at Yale New Haven Hospital.
Clinical Specialties
Therapeutic Radiology; Gastrointestinal Radiotherapy; Pediatric Radiotherapy; Prostate & Genitourinary Radiotherapy; Head & Neck Radiotherapy
News
News
Get In Touch
Contacts
Appointment Number
Mailing Address
Therapeutic Radiology
35 Park St, LL
New Haven, CT 06519
United States
Locations
Hunter Building
Academic Office
15 York Street, Rm 138
New Haven, CT 06510
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.